4.5 Article

Sequence variants in SPAST, SPG3A and HSPD1 in hereditary spastic paraplegia

Journal

JOURNAL OF THE NEUROLOGICAL SCIENCES
Volume 284, Issue 1-2, Pages 90-95

Publisher

ELSEVIER
DOI: 10.1016/j.jns.2009.04.024

Keywords

Hereditary spastic paraplegia; HSP; SPAST; SPG3A; HSPD1; SPG4; SPG13

Funding

  1. Ludvig and Sara Elsass Foundation
  2. Laegeforeningens Research Foundation
  3. Novo Nordisk Foundation
  4. Alzheimer Research Foundation

Ask authors/readers for more resources

Hereditary spastic paraplegia (HSP) is a group of clinically and genetically heterogeneous neurodegenerative disorders characterized by progressive spasticity and weakness in the lower limbs. The most common forms of autosomal dominant HSP, SPG4 and SPG3, are caused by sequence variants in the SPAST and SPG3A genes, respectively. The pathogenic variants are scattered all over these genes and many variants are unique to a specific family. The phenotype in SPG4 patients can be modified by a variant in SPAST (p.Ser44Leu) and recently, a variant in HSPD1, the gene underlying SPG13, was reported as a second genetic modifier in SPG4 patients. In this study HSP patients were screened for variants in SPG3A, SPAST and HSPD1 in order to identify disease causing variations. SPAST was sequenced in all patients whereas subsets were sequenced in HSPD1 and in selected exons of SPG3A. SPG4 patients and their HSP relatives were genotyped for the modifying variant in HSPD1. We report six new sequence variants in SPAST including a fourth non synonymous sequence variant in exon 1 and two synonymous changes of which one has been found in a HSP patient previously, but never in controls. Of the novel variants in SPAST four were interpreted as disease causing. In addition one new disease causing sequence variant and one non pathogenic non synonymous variant were found in SPG3A. In HSPD1 we identified a sporadic patient homozygote for the potential modifying variation. The effect of the modifying HSPD1 variation was not supported by identification in one SPG4 family. (C) 2009 Elsevier B. V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Neurosciences

Novel Homozygous Truncating Variant Widens the Spectrum of Early-Onset Multisystemic SYNE1 Ataxia

William Kristian Karlsson, Joan Lilja Sunnleyg Hojgaard, Anna Vilhelmsen, Clarissa Crone, Birgit Andersen, Ian Law, Lisbeth Birk Moller, Troels Tolstrup Nielsen, Emilie Neerup Nielsen, Thomas Krag, Kirsten Svenstrup, Jorgen Erik Nielsen

Summary: Pathogenic variants in the SYNE1 gene can lead to a range of symptoms from pure ataxia to multisystemic disease. This case study presents a novel homozygous truncating variant in the SYNE1 gene in a 20-year-old female patient with early-onset cerebellar deficits, motor neuron involvement, and cognitive deficits, expanding the understanding of the phenotypic spectrum associated with SYNE1 mutations. The findings also reveal unique neuroimaging and electrophysiological abnormalities that further characterize the disease presentation.

CEREBELLUM (2022)

Article Genetics & Heredity

Phenotypic spectrum and clinical course of single large-scale mitochondrial DNA deletion disease in the paediatric population: a multicentre study

Kristoffer Bjorkman, John Vissing, Elsebet ostergaard, Laurence A. Bindoff, Irenaeus F. M. de Coo, Martin Engvall, Omar Hikmat, Pirjo Isohanni, Gittan Kollberg, Christopher Lindberg, Kari Majamaa, Karin Naess, Johanna Uusimaa, Mar Tulinius, Niklas Darin

Summary: This study describes the clinical spectrum of pediatric-onset syndromes associated with large-scale mitochondrial DNA deletions (LMD). The study found a wider range of multisystem involvement compared to previous studies, likely due to longer follow-up.

JOURNAL OF MEDICAL GENETICS (2023)

Article Genetics & Heredity

Preclinical Research in McArdle Disease: A Review of Research Models and Therapeutic Strategies

Monica Villarreal-Salazar, Astrid Brull, Gisela Nogales-Gadea, Antoni L. Andreu, Miguel A. Martin, Joaquin Arenas, Alfredo Santalla, Alejandro Lucia, John Vissing, Thomas O. Krag, Tomas Pinos

Summary: In this study, the existing in vitro and in vivo preclinical models for McArdle disease are described, and the insights provided by these models are reviewed. Despite some differences from the typical patient phenotype, these models allow for a thorough study of the different features of the disease and serve as a necessary preclinical step to evaluate treatment efficacy and safety.

GENES (2022)

Article Biochemistry & Molecular Biology

Growth Factors Do Not Improve Muscle Function in Young or Adult mdx Mice

Tue L. Nielsen, Tessa M. Hornsyld, Tomas Pinos, Camilla Brolin, John Vissing, Thomas O. Krag

Summary: This study found that the growth factor cocktail did not significantly improve the functional level of mdx model during treatment, despite positive effects on some muscle types at a molecular level. Additionally, histopathology at the end of the treatment revealed signs of inflammation.

BIOMEDICINES (2022)

Meeting Abstract Clinical Neurology

Nutritional status and bone health in pediatric patients with low skeletal muscle mass

M. Naume, C. Hoi-Hansen, A. Born, M. Horby, L. Borgwardt, J. Vissing, D. Staerk, M. Orngreen

NEUROMUSCULAR DISORDERS (2022)

Meeting Abstract Clinical Neurology

Clinical differences between ocular and generalized myasthenia gravis

K. Axelsen, R. Andersen, J. Vissing, N. Witting

NEUROMUSCULAR DISORDERS (2022)

Article Pediatrics

Metabolic assessment in children with neuromuscular disorders shows risk of liver enlargement, steatosis and fibrosis

Marie Mostue Naume, Marianne Horby Jorgensen, Christina Engel Hoi-Hansen, Alfred Peter Born, John Vissing, Lise Borgwardt, Dorte Marianne Rohde Staerk, Mette Cathrine Orngreen

Summary: The aim of this study was to assess the metabolic and nutritional status of children with neuromuscular disorders, particularly focusing on the liver and bone mineral density. The study included 44 children, and assessments were conducted using various methods including ultrasound, blood samples, and diet registration. The findings showed that liver involvement was present in 31.0% of patients, while low bone mineral density was found in 44.0%. Vitamin D insufficiency or deficiency was also detected in 22.6% of patients. This study highlights the importance of monitoring liver function and nutrition in children with neuromuscular disorders.

ACTA PAEDIATRICA (2023)

Article Biology

OxPhos defects cause hypermetabolism and reduce lifespan in cells and in patients with mitochondrial diseases

Gabriel Sturm, Kalpita R. Karan, Anna S. Monzel, Balaji Santhanam, Tanja Taivassalo, Celine Bris, Sarah A. Ware, Marissa Cross, Atif Towheed, Albert Higgins-Chen, Meagan J. McManus, Andres Cardenas, Jue Lin, Elissa S. Epel, Shamima Rahman, John Vissing, Bruno Grassi, Morgan Levine, Steve Horvath, Ronald G. Haller, Guy Lenaers, Douglas C. Wallace, Marie-Pierre St-Onge, Saeed Tavazoie, Vincent Procaccio, Brett A. Kaufman, Erin L. Seifert, Michio Hirano, Martin Picard

Summary: A meta-analysis of mitochondrial disease patients demonstrates that OxPhos defects contribute to hypermetabolism. Patient-derived fibroblast experiments confirm that mitochondrial OxPhos defects induce cell-autonomous hypermetabolism, which is associated with accelerated telomere shortening and epigenetic aging.

COMMUNICATIONS BIOLOGY (2023)

Article Neurosciences

Cerebellar and subcortical atrophy contribute to psychiatric symptoms in frontotemporal dementia

Aurelie P. Bussy, Jake P. Levy, Tristin Best, Raihaan Patel, Lani Cupo, Tim Van Langenhove, Jorgen E. Nielsen, Yolande Pijnenburg, Maria Landqvist M. Waldo, Anne M. L. Remes, Matthias L. Schroeter, Isabel Santana, Florence Pasquier, Markus Otto, Adrian Danek, Johannes Levin, Isabelle Le Ber, Rik Vandenberghe, Matthis Synofzik, Fermin Moreno, Alexandre de Mendonca, Raquel Sanchez-Valle, Robert Laforce, Tobias Langheinrich, Alexander Gerhard, Caroline R. Graff, Chris R. Butler, Sandro Sorbi, Lize Jiskoot, Harro C. Seelaar, John C. van Swieten, Elizabeth Finger, Maria Carmela Tartaglia, Mario Masellis, Pietro Tiraboschi, Daniela Galimberti, Barbara B. Borroni, James B. Rowe, Martina D. Bocchetta, Jonathan D. A. Rohrer, Gabriel A. Devenyi, M. Mallar Chakravarty, Simon Ducharme

Summary: Recent studies have shown that early cerebellar and subcortical changes are seen in the progression of genetic frontotemporal dementia due to specific gene mutations. This study aimed to investigate the relationship between cerebellar and subcortical atrophy and neuropsychiatric symptoms across different genetic mutations in FTD.

HUMAN BRAIN MAPPING (2023)

Article Clinical Neurology

Diagnosis and management of metabolic myopathies

Salman F. Bhai, John Vissing

Summary: Metabolic myopathies are rare inherited disorders that disrupt energy production, leading to symptoms such as exercise intolerance, rhabdomyolysis, and weakness in skeletal muscles. Diagnosis can be challenging due to non-specific and dynamic symptoms, as well as conditions that mimic metabolic myopathies. Next generation sequencing can help clinicians recognize typical clinical phenotypes and shorten diagnosis time. With improved molecular testing accessibility, clinicians should be knowledgeable in interpreting variants of uncertain significance relevant to metabolic myopathies. Once diagnosed, patients can improve their quality of life, engage in exercise safely, and reduce episodes of rhabdomyolysis through diet and lifestyle modifications.

MUSCLE & NERVE (2023)

Correction Multidisciplinary Sciences

Systematic cascade screening in the Danish Fabry Disease Centre: 20 years of a national single-centre experience (vol 17, e0277767, 2022)

Grigoris Effraimidis, Ase Krogh Rasmussen, Morten Dunoe, Lis F. Hasholt, Flemming Wibrand, Soren S. Sorensen, Allan M. Lund, Lars Kober, Henning Bundgaard, Puriya D. W. Yazdanfard, Peter Oturai, Vibeke A. Larsen, Victor Hugo Fraga de Abreu, Lotte Hahn Enevoldsen, Tatiana Kristensen, Kirsten Svenstrup, Margrethe Bastholm Bille, Farah Arif, Mette Mogensen, Mads Klokker, Vibeke Backer, Caroline Kistorp, Ulla Feldt-Rasmussen

PLOS ONE (2023)

Article Nutrition & Dietetics

Patient-Reported Experiences with a Low-Carbohydrate Ketogenic Diet: An International Survey in Patients with McArdle Disease

Nicoline Lokken, Nicol C. C. Voermans, Linda K. Andersen, Walaa Karazi, Stacey L. L. Reason, Heidi Zweers, Gustav Wilms, Alfredo Santalla, Edward Susanibar, Alejandro Lucia, John Vissing

Summary: The low-carbohydrate ketogenic diet (LCKD) has been increasingly used as a potential treatment option for individuals with McArdle disease. This study aimed to collect patient-reported experiences with a LCKD and found that one-third of the McArdle disease cohort had tried a LCKD. The majority of individuals reported positive effects on core symptoms, while adverse effects were rare and mild to moderate.

NUTRIENTS (2023)

Correction Clinical Neurology

New genotype-phenotype correlations in a large European cohort of patients with sarcoglycanopathy (vol 143, pg 2696, 2020)

Jorge Alonso-Perez, Lidia Gonzalez-Quereda, Luca Bello, Michela Guglieri, Volker Straub, Pia Gallano, Claudio Semplicini, Elena Pegoraro, Vittoria Zangaro, Andres Nascimento, Carlos Ortez, Giacomo Pietro Comi, Leroy ten Dam, Marianne De Visser, A. J. van der Kooi, Cristina Garrido, Manuela Santos, Ulrike Schara, Andrea Gangfuss, Nicoline Lokken, Jesper Helbo Storgaard, John Vissing, Benedikt Schoser, Gabriele Dekomien, Bjarne Udd, Johanna Palmio, Adele D'Amico, Luisa Politano, Vincenzo Nigro, Claudio Bruno, Chiara Panicucci, Anna Sarkozy, Omar Abdel-Mannan, Alicia Alonso-Jimenez, Kristl G. Claeys, David Gomez-Andres, Francina Munell, Laura Costa-Comellas, Jana Haberlova, Marie Rohlenova, De Vos Elke, Jan L. De Bleecker, Cristina Dominguez-Gonzalez, Giorgio Tasca, Claudia Weiss, Nicolas Deconinck, Roberto Fernandez-Torron, Adolfo Lopez de Munain, Ana Camacho-Salas, Bela Melegh, Kinga Hadzsiev, Lea Leonardis, Blaz Koritnik, Matteo Garibaldi, Juan Carlos de Leon-Hernandez, Edoardo Malfatti, Arturo Fraga-Bau, Isabelle Richard, Isabel Illa, Jordi Diaz-Manera

BRAIN (2023)

Meeting Abstract Clinical Neurology

ROZANOLIXIZUMAB IN GENERALIZED MYASTHENIA GRAVIS: RESPONDER ANALYSES FROM THE RANDOMIZED PHASE 3 MYCARING STUDY

Vera Bril, Artur Druzdz, Julian Grosskreutz, Ali Habib, Renato Mantegazza, Sabrina Sacconi, Kimiaki Utsugisawa, John Vissing, Tuan Vu, Marion Boehnlein, Ali Bozorg, Maryam Gayfieva, Franz Woltering, Henry Kaminski

MUSCLE & NERVE (2022)

Meeting Abstract Clinical Neurology

EFFICACY OF ROZANOLIXIZUMAB IN MUSCLE SPECIFIC KINASE ANTIBODY-POSITIVE GENERALIZED MYASTHENIA GRAVIS: OUTCOMES FROM THE RANDOMIZED, PHASE 3 MYCARING STUDY

Ali Habib, Henry Kaminski, Artur Druzdz, Julian Grosskreutz, Renato Mantegazza, Sabrina Sacconi, Kimiaki Utsugisawa, John Vissing, Tuan Vu, Marion Boehnlein, Bernhard Greve, Franz Woltering, Vera Bril

MUSCLE & NERVE (2022)

No Data Available